$FEMY News

Last published 1w ago

1w agoFEMYFemasys Appoints John Moorhead to Board of DirectorsGlobeNewswireATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the
3w agoFEMYFemasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNsGlobeNewswireATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the
4w agoFEMYFemasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth ControlGlobeNewswireATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the
1mo agoFEMYFemasys to Exhibit at the ASRM 2026 Scientific Congress & ExpoGlobeNewswireATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the
1mo agoFEMYFemasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s CareGlobeNewswire-- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) --
2mo agoFEMYFemasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility PortfolioGlobeNewswireATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the
2mo agoFEMYFemasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care LocationsGlobeNewswire-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys
2mo agoFEMYFemasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®GlobeNewswireATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the
2mo agoFEMYFemasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate UpdateGlobeNewswire-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14,
3mo agoFEMYFemasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer PatentsGlobeNewswire-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a
3mo agoFEMYFemasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 MillionGlobeNewswire-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative
4mo agoFEMYFemasys Regains Compliance with Nasdaq Listing RequirementsGlobeNewswireATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women
6mo agoFEMYFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterGlobeNewswireATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women
6mo agoFEMYFemasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateGlobeNewswireATLANTA, May 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
6mo agoFEMYFemasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® CompleteGlobeNewswire-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc.
6mo agoFEMYFemasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026GlobeNewswireATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women
6mo agoFEMYFemasys Drives International Growth with Israeli Market Entry for Fertility PortfolioGlobeNewswire-- Partnership with AMI Technologies Positions FemaSeed® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions -- ATLANTA, April 16, 2026 (GLOBE NEWSWIRE) --
7mo agoFEMYFemasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial GrowthGlobeNewswireATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women
7mo agoFEMYFemasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate UpdateGlobeNewswireATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
8mo agoFEMYFemasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial EnrollmentGlobeNewswire-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE
8mo agoFEMYFemasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
8mo agoFEMYFemasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market AccessGlobeNewswire-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading
8mo agoFEMYFemasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal InseminationGlobeNewswire-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making
9mo agoFEMYFemasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio ProductsGlobeNewswireATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
10mo agoFEMYFemasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementGlobeNewswireATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) ("Femasys" or the "Company"), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and
10mo agoFEMYFemasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based CareGlobeNewswireATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
10mo agoFEMYFemasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic DeviceGlobeNewswire-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys
11mo agoFEMY PMCBPharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital DeploymentBusiness WirePharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's strategic approach to
12mo agoFEMYFemasys Announces Third Quarter Financial Results for 2025GlobeNewswire– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025
1y agoFEMYFemasys Advances Global Growth with Second Partner Order for FemBloc® in EuropeGlobeNewswire-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company's presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc.
1y agoFEMYFemasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 MillionGlobeNewswire-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for
1y agoFEMYFemasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in EuropeGlobeNewswire--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making
1y agoFEMYFemasys to Exhibit at the ASRM 2025 Scientific Congress & ExpoGlobeNewswireSAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women
1y agoFEMYFemasys Accelerates European Growth for FemBloc® with Kebomed PartnershipGlobeNewswireATLANTA, Sept.
1y agoFEMYFemasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeedGlobeNewswireATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
1y agoFEMYFemasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®GlobeNewswireATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
1y agoFEMYFemasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New ZealandGlobeNewswireATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide,
1y agoFEMYFemasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control PortfoliosGlobeNewswire--Existing investors, including Femasys' largest shareholders, reaffirm confidence in Femasys' strategy for growth and impact in women's health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY),
1y agoFEMYFemasys Announces Pricing of $8.0 Million Underwritten Public OfferingGlobeNewswireATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio
1y agoFEMYFemasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility PlatformGlobeNewswire-- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth -- ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Femasys Inc.
1y agoFEMYFemasys Secures UK Regulatory Approval of FemBloc Permanent Birth ControlGlobeNewswire--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical
1y agoFEMYFemasys Announces Second Quarter Financial Results for 2025GlobeNewswire-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making
1y agoFEMYFemasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global ExpansionGlobeNewswire--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical
1y agoFEMYFemasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue DiagnosticGlobeNewswire-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator
1y agoFEMYFemasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth ControlGlobeNewswireATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive,
1y agoFEMYFemasys Names New Chief Commercial Officer to Drive Execution and Global GrowthGlobeNewswire--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys,
1y agoFEMYFemasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 LocationsGlobeNewswire-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical
1y agoFEMYFemasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 MillionGlobeNewswireATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio
1y agoFEMYFemasys Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementGlobeNewswireATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio
1y agoFEMYFemasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate UpdateGlobeNewswire-- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system